Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
ARKO Petroleum Corp Q1 2026 Earnings Call - IPO-Fueled Balance Sheet Strength and Dealerization Tailwind Drive Margin Expansion
ARKO Petroleum delivered a robust first quarter, with adjusted EBITDA rising 18% year-over-year to $36.4 million, driven by disciplined margin capture and a structural shift in its business mix. The c...
- Adjusted EBITDA rose 18% year-over-year to $36.4 million, reflecting strong margin capture across segments despite fuel cost volatility.
- Net leverage dropped to 2.1 times following the IPO, with $206.7 million in proceeds used to reduce debt and strengthen the balance sheet.
- Wholesale fuel contribution increased 14.2% to $22.9 million, driven by a 2.8% rise in gallon volume and higher cents-per-gallon margins.
- +9 more takeaways
Array Technologies Q1 2026 Earnings Call - Record $2.4B Order Book Driven by New Product Momentum
Array Technologies delivered a strong Q1 2026, reporting $223M in revenue and $29M in adjusted EBITDA, with adjusted gross margins expanding to 30.7%. The company set a record order book of $2.4B, sup...
- Q1 2026 revenue hit $223 million, with adjusted gross margins expanding 620 basis points sequentially to 30.7%, driven by domestic mix, productivity gains, and one-time tariff/45X benefits.
- Adjusted EBITDA surged 157% to $29 million, while GAAP net loss narrowed to $14 million, reflecting improved operational execution and cost discipline.
- The company recorded a record $2.4 billion order book, marking its second consecutive quarter with a 2.0x book-to-bill ratio and a 1.3x trailing 12-month ratio.
- +7 more takeaways
Genpact Limited Q1 2026 Earnings Call - Agentic Revenue Nearly Doubles as Company Pivots to AI-Driven Operations
Genpact delivered a record start to fiscal 2026, with total revenue rising 6.7% year-over-year to $1.296 billion and adjusted diluted EPS jumping 16.7%. The real story is the acceleration in Advanced ...
- Total revenue grew 6.7% year-over-year to $1.296 billion, marking a record start to fiscal 2026.
- Advanced Technology Solutions revenue accelerated 24% year-over-year to $345 million, now accounting for 27% of total revenue.
- Contract values for agentic solutions nearly doubled from all of 2025, with over 50% of cumulative awarded value coming from new clients.
- +9 more takeaways
Viking Therapeutics Q1 2026 Earnings Call - Subcutaneous and Oral VK2735 Programs Advance to Phase III with $600M War Chest
Viking Therapeutics is accelerating its obesity franchise with both subcutaneous and oral formulations of its lead compound VK2735 moving into phase III registration trials. The company completed enro...
- VK2735 subcutaneous phase III VANQUISH-1 and VANQUISH-2 trials are fully enrolled, with patients randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo over 78 weeks.
- Oral VK2735 formulation advances to phase III development, with initiation planned for Q4 2026 following successful phase II VENTURE oral study results showing up to 12.2% weight loss at 13 weeks.
- Maintenance dosing study expanded to eight subcutaneous cohorts testing monthly and every-other-week regimens, with results expected in Q3 2026 to inform VANQUISH extension trials.
- +7 more takeaways
Exagen Q1 2026 Earnings Call - Record Revenue Driven by ASP Expansion and Commercial Scaling
Exagen reported a record first quarter of 2026, with revenue climbing 12% year-over-year to $17.3 million, fueled by a 10% jump in testing volume and a 6% year-over-year increase in trailing twelve-mo...
- Record Q1 2026 revenue of $17.3 million, up 12% year-over-year, driven by both volume and price growth.
- Testing volume grew 10% year-over-year, outpacing the estimated 5% market growth rate for the autoimmune testing category.
- Trailing twelve-month ASP expanded 6% to $444, marking the 12th consecutive quarter of ASP growth and smoothing out quarterly variability.
- +7 more takeaways
Heron Therapeutics Q1 2026 Earnings Call - Weather Headwinds Mask Strong Commercial Momentum and Pricing Discipline
Heron Therapeutics reported Q1 2026 net sales of $34.7 million, missing short-term targets due to two weeks of severe winter weather that disrupted elective surgeries and compounded typical seasonal s...
- Q1 2026 net sales totaled $34.7 million, below plan due to two weeks of severe winter weather that disrupted elective surgeries and compounded typical seasonal softness.
- March net sales exceeded $15 million, signaling a strong sequential recovery and reinforcing confidence in full-year 2026 guidance of $173 million to $183 million in net product sales.
- Growth margins came in at 69%, temporarily depressed by a secondary CINVANTI supplier contract; management expects normalization to the mid-70s range as the secondary inventory winds down over the next two quarters.
- +7 more takeaways
Leidos Q1 2026 Earnings Call - NorthStar 2030 Growth Strategy Accelerates with Strategic Acquisitions and Defense Tech Momentum
Leidos delivered a robust Q1 2026, with revenue rising 4% year-over-year to $4.4 billion and adjusted EBITDA margin holding steady at 14%. The company used its strong cash generation to close the ENTR...
- Q1 2026 revenue reached $4.4 billion, up 4% year-over-year, with 3% organic growth driven by robust demand in Intelligence and Digital and Homeland segments.
- Adjusted EBITDA margin held at 14%, generating $614 million in profit, while non-GAAP diluted EPS grew 5% to $3.13.
- Leidos raised full-year 2026 revenue guidance by $500 million to $18.0–$18.4 billion, increased non-GAAP diluted EPS guidance by $0.05 to $12.10–$12.50, and boosted operating cash flow guidance by $50 million to approximately $1.8 billion.
- +7 more takeaways
Uniti Group Q1 2026 Earnings Call - Fiber Infrastructure Revenue Growth Accelerates Amid AI Build Cycle
Uniti Group delivered a strong first quarter 2026, driven by robust fiber infrastructure growth and disciplined execution. The company reported a 15% year-over-year increase in total fiber revenue, wi...
- Total fiber revenue grew 15% year-over-year in Q1 2026, with Kinetic consumer fiber revenue surging 26%.
- Kinetic added 30,000 net new fiber subscribers, ending the quarter with 564,000 total fiber subscribers.
- Fiber Infrastructure bookings reached the third highest on record at approximately $1.6 million in MRR.
- +7 more takeaways
Bicara Therapeutics Q1 2026 Earnings Call - FICERA Pivotal Trial Enrollment on Track for Mid-2027 Interim Analysis, $540M Cash Position Secures Launch Readiness
Bicara Therapeutics is accelerating toward a potential accelerated approval for FICERA, its bifunctional EGFR-directed antibody combined with a TGF-beta ligand trap, in frontline recurrent and metasta...
- FICERA pivotal FORTIFY-HN01 trial enrollment is on track to be substantially complete by year-end, positioning the company for an interim analysis focused on overall response rate with 6-month durability for potential accelerated approval in mid-2027.
- Three-year follow-up data from phase I-B cohorts will be presented at ASCO 2026, showing median overall survival of 21.3 months and median duration of response of 21.7 months for the 1,500 mg weekly plus pembrolizumab dose, more than doubling OS compared to standard-of-care pembrolizumab in HPV-negative patients.
- Bicara is initiating a parallel phase II study to evaluate a 12-week loading phase of 1,500 mg weekly followed by a 2,250 mg every-3-week maintenance regimen, aiming to balance efficacy, tolerability, and patient convenience while satisfying FDA Project Optimus requirements.
- +7 more takeaways
Liquidia Corporation Q1 2026 Earnings Call - YUTREPIA Sales Surge Drives Third Consecutive Quarter of Profitability
Liquidia Corporation reported a 44% sequential increase in first quarter 2026 net product sales for YUTREPIA, reaching $129.9 million and marking its third consecutive quarter of profitability. The co...
- YUTREPIA Q1 2026 net product sales reached $129.9 million, a 44% sequential increase from Q4 2025, demonstrating sustained commercial momentum.
- The company reported its third consecutive quarter of profitability, with net income rising to $52.9 million and non-GAAP adjusted EBITDA tripling to $71.2 million.
- Liquidia has achieved approximately 4,500 unique patient prescriptions and 980 prescribing physicians since YUTREPIA's launch, with physician retention rates showing strong depth of use.
- +7 more takeaways